Literature DB >> 20679438

Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon.

Teresa M Wozniak1, Bernadette M Saunders, Anthony A Ryan, Warwick J Britton.   

Abstract

Protective immunity against tuberculosis (TB) requires the integrated response of a network of lymphocytes. Both gamma interferon (IFN-γ)- and interleukin 17 (IL-17)-secreting CD4(+) T cells have been identified in subjects with latent TB infection and during experimental Mycobacterium tuberculosis infection, but the contribution of Th17 cells to protective immunity is unclear. To examine their protective effects in vivo, we transferred mycobacterium-specific IL-17- and IFN-γ-secreting CD4(+) T cells isolated from M. tuberculosis BCG-immunized IL-12p40(-/-) and IFN-γ(-/-) or wild-type mice, respectively, into M. tuberculosis-infected IL-12p40(-/-) or RAG(-/-) mice. In the absence of IL-12 and IL-23, neither IL-17-secreting (Th17) nor IFN-γ-secreting (Th1) BCG-specific T cells expanded or provided protection against M. tuberculosis. In RAG(-/-) recipients with an intact IL-12/IL-23 axis, both Th17 and Th1 cells were activated and induced significant protection against M. tuberculosis. The reduction in the bacterial load following transfer of IFN-γ(-/-) Th17 cells was associated with significant prolongation of survival compared to recipients of naïve IFN-γ(-/-) T cells. This effect was at the cost of an increased inflammatory infiltrate characterized by an excess of neutrophils. Therefore, Th17 cells can provide IFN-γ-independent protection against M. tuberculosis, and this effect may contribute to the early control of M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679438      PMCID: PMC2950338          DOI: 10.1128/IAI.01392-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

4.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.

Authors:  Heon Park; Zhaoxia Li; Xuexian O Yang; Seon Hee Chang; Roza Nurieva; Yi-Hong Wang; Ying Wang; Leroy Hood; Zhou Zhu; Qiang Tian; Chen Dong
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Transforming growth factor-beta induces development of the T(H)17 lineage.

Authors:  Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

6.  IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available.

Authors:  Shabaana A Khader; John E Pearl; Kaori Sakamoto; Leigh Gilmartin; Guy K Bell; Dawn M Jelley-Gibbs; Nico Ghilardi; Fred deSauvage; Andrea M Cooper
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

7.  A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion.

Authors:  W J Britton; N Meadows; D A Rathjen; D R Roach; H Briscoe
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

8.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

9.  The development and impact of tuberculosis vaccines.

Authors:  Douglas Young; Christopher Dye
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

10.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.

Authors:  Spencer C Liang; Xiang-Yang Tan; Deborah P Luxenberg; Riyez Karim; Kyriaki Dunussi-Joannopoulos; Mary Collins; Lynette A Fouser
Journal:  J Exp Med       Date:  2006-09-18       Impact factor: 14.307

View more
  61 in total

Review 1.  Immunomodulation by vitamin D: implications for TB.

Authors:  Rene F Chun; John S Adams; Martin Hewison
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

Review 2.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

3.  Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset.

Authors:  Thomas Lindenstrøm; Joshua Woodworth; Jes Dietrich; Claus Aagaard; Peter Andersen; Else Marie Agger
Journal:  Infect Immun       Date:  2012-07-30       Impact factor: 3.441

Review 4.  IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS.

Authors:  Govardhana Rao Yannam; Tanuja Gutti; Larisa Y Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-24       Impact factor: 4.147

Review 5.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

Review 6.  Quest for correlates of protection against tuberculosis.

Authors:  Kamlesh Bhatt; Sheetal Verma; Jerrold J Ellner; Padmini Salgame
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 7.  Immunology of Mycobacterium tuberculosis Infections.

Authors:  Jonathan Kevin Sia; Jyothi Rengarajan
Journal:  Microbiol Spectr       Date:  2019-07

Review 8.  Th1 cytokines, true functional signatures for protective immunity against TB?

Authors:  Gucheng Zeng; Guoliang Zhang; Xinchun Chen
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

9.  Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9.

Authors:  Archana Gopalakrishnan; Jillian Dietzold; Padmini Salgame
Journal:  Cell Immunol       Date:  2015-12-30       Impact factor: 4.868

Review 10.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.